Literature DB >> 23103200

Usefulness of inducible ventricular tachycardia to predict long-term adverse outcomes in arrhythmogenic right ventricular cardiomyopathy.

Ardan M Saguner1, Argelia Medeiros-Domingo, Moritz A Schwyzer, Chol-Jun On, Laurent M Haegeli, Thomas Wolber, David Hürlimann, Jan Steffel, Nazmi Krasniqi, Sina Rüeger, Leonhard Held, Thomas F Lüscher, Corinna Brunckhorst, Firat Duru.   

Abstract

The role of the electrophysiologic (EP) study for risk stratification in patients with arrhythmogenic right ventricular cardiomyopathy is controversial. We investigated the role of inducible sustained monomorphic ventricular tachycardia (SMVT) for the prediction of an adverse outcome (AO), defined as the occurrence of cardiac death, heart transplantation, sudden cardiac death, ventricular fibrillation, ventricular tachycardia with hemodynamic compromise or syncope. Of 62 patients who fulfilled the 2010 Arrhythmogenic Right Ventricular Cardiomyopathy Task Force criteria and underwent an EP study, 30 (48%) experienced an adverse outcome during a median follow-up of 9.8 years. SMVT was inducible in 34 patients (55%), 22 (65%) of whom had an adverse outcome. In contrast, in 28 patients without inducible SMVT, 8 (29%) had an adverse outcome. Kaplan-Meier analysis showed an event-free survival benefit for patients without inducible SMVT (log-rank p = 0.008) with a cumulative survival free of an adverse outcome of 72% (95% confidence interval [CI] 56% to 92%) in the group without inducible SMVT compared to 26% (95% CI 14% to 50%) in the other group after 10 years. The inducibility of SMVT during the EP study (hazard ratio [HR] 2.99, 95% CI 1.23 to 7.27), nonadherence (HR 2.74, 95% CI 1.3 to 5.77), and heart failure New York Heart Association functional class II and III (HR 2.25, 95% CI 1.04 to 4.87) were associated with an adverse outcome on univariate Cox regression analysis. The inducibility of SMVT (HR 2.52, 95% CI 1.03 to 6.16, p = 0.043) and nonadherence (HR 2.34, 95% CI 1.1 to 4.99, p = 0.028) remained as significant predictors on multivariate analysis. This long-term observational data suggest that SMVT inducibility during EP study might predict an adverse outcome in patients with arrhythmogenic right ventricular cardiomyopathy, advocating a role for EP study in risk stratification.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23103200     DOI: 10.1016/j.amjcard.2012.09.025

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  16 in total

Review 1.  Arrhythmogenic ventricular cardiomyopathy: A paradigm shift from right to biventricular disease.

Authors:  Ardan M Saguner; Corinna Brunckhorst; Firat Duru
Journal:  World J Cardiol       Date:  2014-04-26

2.  Arrhythmogenic Cardiomyopathy: Electrical and Structural Phenotypes.

Authors:  Deniz Akdis; Corinna Brunckhorst; Firat Duru; Ardan M Saguner
Journal:  Arrhythm Electrophysiol Rev       Date:  2016-08

Review 3.  Arrhythmogenic Right Ventricular Cardiomyopathy: Risk Stratification and Indications for Defibrillator Therapy.

Authors:  Alessandro Zorzi; Ilaria Rigato; Barbara Bauce; Kalliopi Pilichou; Cristina Basso; Gaetano Thiene; Sabino Iliceto; Domenico Corrado
Journal:  Curr Cardiol Rep       Date:  2016-06       Impact factor: 2.931

Review 4.  Risk Stratification in Arrhythmogenic Right Ventricular Cardiomyopathy.

Authors:  Hugh Calkins; Domenico Corrado; Frank Marcus
Journal:  Circulation       Date:  2017-11-21       Impact factor: 29.690

5.  Sex hormones affect outcome in arrhythmogenic right ventricular cardiomyopathy/dysplasia: from a stem cell derived cardiomyocyte-based model to clinical biomarkers of disease outcome.

Authors:  Deniz Akdis; Ardan M Saguner; Khooshbu Shah; Chuanyu Wei; Argelia Medeiros-Domingo; Arnold von Eckardstein; Thomas F Lüscher; Corinna Brunckhorst; H S Vincent Chen; Firat Duru
Journal:  Eur Heart J       Date:  2017-05-14       Impact factor: 29.983

6.  A classic case of arrhythmogenic right ventricular cardiomyopathy (ARVC) and literature review.

Authors:  Htun Latt; Thein Tun Aung; Chanwit Roongsritong; David Smith
Journal:  J Community Hosp Intern Med Perspect       Date:  2017-06-06

Review 7.  Catheter Ablation of Ventricular Tachycardia in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy.

Authors:  Fa Po Chung; Chin Yu Lin; Yenn Jiang Lin; Shih Lin Chang; Li Wei Lo; Yu Feng Hu; Ta Chuan Tuan; Tze Fan Chao; Jo Nan Liao; Ting Yung Chang; Shih Ann Chen
Journal:  Korean Circ J       Date:  2018-10       Impact factor: 3.243

8.  Diagnostic and therapeutic strategies for arrhythmogenic right ventricular dysplasia/cardiomyopathy patient.

Authors:  Weijia Wang; Cynthia A James; Hugh Calkins
Journal:  Europace       Date:  2019-01-01       Impact factor: 5.214

9.  Treatment of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: An International Task Force Consensus Statement.

Authors:  Domenico Corrado; Thomas Wichter; Mark S Link; Richard N W Hauer; Frank E Marchlinski; Aris Anastasakis; Barbara Bauce; Cristina Basso; Corinna Brunckhorst; Adalena Tsatsopoulou; Harikrishna Tandri; Matthias Paul; Christian Schmied; Antonio Pelliccia; Firat Duru; Nikos Protonotarios; Na Mark Estes; William J McKenna; Gaetano Thiene; Frank I Marcus; Hugh Calkins
Journal:  Circulation       Date:  2015-07-27       Impact factor: 29.690

Review 10.  Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement.

Authors:  Domenico Corrado; Thomas Wichter; Mark S Link; Richard Hauer; Frank Marchlinski; Aris Anastasakis; Barbara Bauce; Cristina Basso; Corinna Brunckhorst; Adalena Tsatsopoulou; Harikrishna Tandri; Matthias Paul; Christian Schmied; Antonio Pelliccia; Firat Duru; Nikos Protonotarios; N A Mark Estes; William J McKenna; Gaetano Thiene; Frank I Marcus; Hugh Calkins
Journal:  Eur Heart J       Date:  2015-07-27       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.